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Oral Cimetidine, Ranitidine, and Famotidine as 
Determined by Echocardiography 
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Michael J .  Shea, M.D.,  Ronald E. Dechert, M.S., and Barry E.  Bleske, Pharm.D. 
Study Objective. To evaluate the influence of cimetidine, ranitidine, famotidine, 
Design. Randomized, four-way crossover trial. 
Setting. Echocardiography laboratory at a university hospital. 
Participants. Twelve healthy volunteers. 
Interventions. Volunteers received oral treatment with placebo, cimetidine 800 
mg, ranitidine 300 mg, or famotidine 40 mg once/day for 7 days. 
Measurements and Main Results. On the seventh day of each stud? phase, 2 
hours after administration of the final dose, each subject underwent cardiac 
echocardiography and Doppler flow studies. No significant differences were 
detected in ejection fraction, peak flow velocity, or percentage fractional 
shortening among the treatment phases. A large degree of variability in ejection 
fraction was observed, with some subjects experiencing marked decreases. 
Conclusion. The histamine-2 (Hl)-receptor antagonists had no effect on the 
hemodynamic variables as determined by echocardiography. The variability in 
the hemodynamic response may in part explain the conflicting results reported 
in the literature. It also raises the question as to whether certain individuals are 
more sensitive to the potential cardiac effects of H2-receptor antagonists. 
and placebo on cardiac performance as determined by echocardiography. 
(Pharmacotherapy 1995; 1x2):  158-163) 
Histamine-2 (Hz)-receptor antagonists are used 
to treat a variety of acid-peptic disorders, including 
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gastric ulcer, duodenal ulcer, Zollinger-Ellison 
syndrome, and gastroesophageal reflux disease. 
Although these agents inhibit gastric acid secretion, 
they may also antagonize the effects of histamine 
on the myocardium.'-3 Stimulation of H1 and HL 
receptors on the myocardium results in a fine 
balance of inotropic effects, with HI receptors 
mediat ing a negative effect and  H2 receptors 
e l ic i t ing a posi t ive effect . l  Under  normal  
conditions, the positive inotropic effect mediated 
by the Hz receptor usually predominates over the 
negative inotropism caused by stimulation of the 
HI  receptor^.^ In vitro s tudies  indicate that 
cimetidine and ranitidine may inhibit histamine's 
positive inotropic effects, resulting in a negative 
inotropic effect on the m y o ~ a r d i u m . ~ - ~  
Studies assessing the impact of H2-receptor 
antagonists on cardiac performance in humans 
have produced conflicting In some 
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studies oral faniotidine, but not cimetidine or 
ranitidine, exerted a negative inotropic effect on 
card i a c p e r f o r ni a n c e . ’-’ 0 t h e r in v e s t i g a t o r s , 
however ,  were unable  to  subs tan t ia te  these 
results,’-’’ and in fact one group demonstrated a 
positive inotropic effect with oral ranitidine. ’‘ The 
reasons for these discrepancies are not clear, but 
they may be d u e  to ihe  iechniques  used  to  
detemmine cardiac function, the agents studied, the 
population examined, the route of administration, 
or the dosage of the H2-receptor antagonist. 
The purpose of this study was to determine the 
effects of the three most commonly prescribed Hz 
antagonists, cimetidine, famotidine, and ranitidine, 
on left ventricular performance as assessed by a 
s tandard t e c hn i  qu e , echo c a r d i o gr a p h y, which 
derives its measurements by direct visualization of 
the heart. Unlike previous studies,’-” this one 
employed once-daily dosing of each drug and 
assessed cardiac performance at steady state (day 
7) using accepted echocardiographic techniques. 
Methods 
Subjects 
The  s tudy  was approved  by the hospital’s 
institutional review board. Twelve volunteers (6 
men, 6 women) were enrolled in this randomized, 
single-blind, four-way, crossover trial and provided 
written informed consent. They were in good 
health as determined by medical history, physical 
examination, electrocardiogram, complete blood 
count, urine pregnancy test (if applicable), and 
serum chemistries. Persons with a history of renal, 
hepatic, or cardiovascular disease were excluded 
from participation, as were women who  were 
pregnant or lactating. Also excluded were those who 
had received any drug known to inhibit or induce 
drug metabolism within 30 days of study entry 
All subjects were nonsmokers and within 20% of 
their ideal body weight (Metropolitan Life Insurance 
Co., 1983). They were drug free, including over- 
the-counter agents, 7 days before study initiation 
and throughout the s tudy period. They were 
requested to refrain from xanthine-containing 
foods and beverages for 24 hours  before each 
assessment of cardiac function. 
Study Design 
In a randomized, crossover manner, each subject 
received oral  doses  of c imet id ine  8 0 0  m g ,  
ranitidine 300 mg, famotidine 40 mg, or placebo 
(lactose tablet) once/day between 3 and 5 P.M. 
every day for 7 days. A 1-week washout period 
separa ted  each of the t reatment  phases  
Compliance with the drug regimens mas dsscssed 
by questioning the participants and bj. tablet 
counts In addition, subjects were queried during 
each s tudy  phase as  to whether  or  not  the)  
experienced any adverse el ents 
On the seventh day of each study phase, after a 
6-hour fast, subjects returned to the hospital where 
they took the study drug with 240 ml of water and 
then underwent noninvasir e cardiac studies 
Noninvasive Assessment of Cardiac Function 
Blood pressure and heart rate were measured in 
triplicate using automated blood pressure devices 
before and 30, 60 ,  and 90  minutes after drug 
administration. Two hours after drug adminis- 
tration, each subject underwent two-dimensional 
echocardiography and Doppler flow studies while 
lying i n  a left la teral  pos i t ion .  These were 
performed by a technician who was blinded to the 
treatment schedule. 
To facilitate the  s tudy,  the s tud ie s  were 
performed using three-phase array echocardio- 
graphic systems, the Interspec/Vingmed Color 
Flow Mapping System 700 (ATLAnterspec 
Cardiology, Ambler, PA), the Ultramark 9 Ultrasound 
System (Advanced Technology Laboratories, Bothell, 
WA), and  the Acuson 128XP/E Computed  
Sonography System (Acuson Corp. ,  Mountain 
View, CA). Three echocardiographic systems 
facilitated echocardiographic assessments of all 12 
volunteers on a single study day. Although there 
were three separate echocardiographic systems and 
three independent technicians, the device and 
technician for a given patient remained constant 
throughout the study (e.g., different systems were 
used for different subjects). The echocardiograms 
were recorded onto videotape and read by two 
technicians who were blinded to the treatment 
schedule. 
Standard two-dimensional echocardiographic 
measurements and Doppler flow velocities were 
obtained according to the guidelines prepared by 
the American Society of Echocardiography as 
outlined briefly.13 Simpson’s rule was used to 
obtain left ventricular volume and ejection fraction. 
Specifically, the endocardial surface of the left 
ventricle was first traced at end diastole (upstroke 
of the R wave) to obtain the end-diastolic volume. 
The end-systolic volume was obtained by tracing 
the  endocard ia l  surface of the  smallest  left 
ventricular cavity. Left ventricular ejection fraction 
(EF) was est imated by  subt rac t ing  the  left 
ventricular volumes during systole (ESV) from left 
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ventricular volumes during diastole (EDV) divided 
by the left \Tentricular volume during diastole 
(EDV) (EF = [EDV - ESV]/EDV).’i The percentage 
fractional shortening (FS), which also measures left 
ventricular function (contractility), was calculated 
as end-diastolic diameter (EDD) minus end-systolic 
diameter (ESD) divided by the product of end- 
diastolic diameter (EDD) multiplied by 100 (FS = 
[EDD-EDS]/[EDD* lOO]). Ascending aortic blood 
flow velocity (peak flow velocity) was obtained by 
Doppler measurements. Peak flow velocities were 
measured from the leading edge of the high- 
frequency opening sound to the leading edge of the 
closing sound of the aortic valve cusps. 
Interobserver variability in EF was evaluated for 
each of the 48 echocardiograms that were read in 
duplicate (data set 1). The average interobserver 
coefficient of var ia t ion was 1 1 . 1 6  f 7 . 7 9 % ;  
however, the coefficient of variation ranged from 
0-27.1% for the data pairs. 
Since inspection of the EF data revealed that in 
33% of the measurements  the coefficient of 
variation exceeded 15%, the videotapes of these 
echocardiograms were reread by two technicians 
who were unaware of the treatment schedule. 
Thus, these echocardiograms had four readings. 
Subsequently, to minimize the variance, the high 
and low observations were discarded and the 
average was obtained for the remaining two 
readings (data set 2). The average interobserver 
coefficient of variation for data set 2 was 6.57 * 
4 . 2 0 % .  In add i t ion ,  d u e  to  the  unexpec ted  
variability observed at o u r  i n s t i t u t ion ,  all 
videotapes were evaluated in a blinded manner by 
an independent laboratory (data set 3). 
For purposes of this analysis the parasternal 
short axis view of the left ventricle at or near the 
papillary muscle tips was used to obtain end-  
diastolic and end-systolic endocardia1 contours, 
and an apical four-chamber view to measure end- 
systolic and end-diastolic long axes. The bullet 
formula for measuring left ventricular volume was 
employed  to  obta in  the  volumes  for the  EF 
calculations. Interobserver variability at the 
independent laboratory yielded a coefficient of 
correlation of 0.78. 
Statistical Analyses 
Statistical analysis of heart rate and  blood 
pressure among the four treatments over time was 
performed using a repeated measures analysis of 
variance. Comparisons among the four regimens 
for EF, percentage fractional shortening, and peak 
flow velocity obtained f rom data  set  1 were 
performed b y  three-way analysis of variance with 
treatment, subject, and period being the class 
\rariables. Differences among the t reatment  
regimens in data sets 2 and 3 were evaluated by 
three-way analysis of var iance.  To evaluate 
whether there was an overall effect of H2-receptor 
antagonists versus placebo on cardiac performance 
(EF, percentage fractional shortening, peak flow 
velocity), for each of the three data sets the mean 
effect obtained during treatment with the HL- 
receptor antagonists ( e .g . ,  mean effect of the 
treatments) was compared with placebo using 
paired Student’s t tests. A paired Student’s t test 
was used  to  compare  the eject ion fract ions 
determined in our laboratory with those obtained 
by the independent laboratory. A p value less than 
0 .05  was set as the critical level for statistical 
significance. The reported data are represented as 
mean and standard deviation unless otherwise 
specified. 
Results 
All 12 subjects completed all four phases of the 
investigation without any complications or adverse 
reactions. They were compliant with study drugs 
and procedures. They ranged in age from 20-43 
years (27.3 f 6.4 yrs), with a weight of 62.8 * 13.2 
kg (range 45-94 kg) and a height of 66.5 f 4 .5  
inches. 
Minor fluctuations in  heart rate and  blood 
pressure occurred  across  the 2 -hour  s tudy ;  
however, no significant differences were observed 
in systolic or diastolic blood pressure or heart rate 
among the treatment phases immediately before 
echocardiography (e.g., at 1 .5  or 2 .0  hrs). 
Data Set 1 
According to the initial data analysis, the mean 
EFs were 58.6 * 8.6%, 57.3 + 5.4%, 55.9 e 5.8%, 
a n d  55.1 f 6 .3% af ter  p lacebo ,  c imet id ine ,  
ranitidine, and famotidine, respectively (p>0.05). 
A large degree of variability in EF was observed 
among the individual subjects (Figure 1). Since 
one subject appeared to be an outlier, the data 
were reanalyzed wi thout  this  subject’s da ta ;  
however this did not significantly alter the results 
(e.g., no significant differences among treatments). 
Therefore, the following are results from all 12 
subjects. 
Differences in EF during the placebo phase 
versus the treatment phases (EF placebo - EF 
treatment) for the individual subjects ranged from - 
12 to 16%, -12.5 to 8%, and -14.5 to 11% during 
cimetidine, ranitidine, and famotidine, respectively 
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Table 1. Ejection Fraction (%) 
Treatment Data Set 1 ' I' ~ a t a  k t  2" Data set 3.1 I' 
70 - 
60- 
it 5 0 -  
: /  4 0 -  
34.1 k 2.9, and 33.6 c 3.7, respectively (p>0.05) 
Placebo 58.6 i 8.6 5Y.Y * 6 2 5Y 1 t 5 Y 
Ciinetidine 57.3 5.-t 57.$ i 5 3 61.0 2 3.1 
Ranitidine 5 5 Y k 5 8  564k5.2 h 0 3 i - t . l  
Farnotidine 5 5 1 i 6 3  55 6 k 6.2 60 Y * 6.2 
The mean differences during the placebo phase 
versus those during cimetidine, ranitidine, and 
famotidine phases were 1.29 * 6.53%, -2.75 * 8.91%, 
and 3.54 c 8.7696, respectively. Decreases in EF 
compared with placebo occurred in nine, seven, 
and seven subjects after the three agents, respectively 
The mean peak flow velocity was 1.11 0.17, 1.06 
c 0.16, 1.10 c 0.18, and 1.07 0.16 cdsecondafter 
placebo, cimetidine, ranitidine, and famotidine, 
respectively (p>O.O5). The mean percentages 
fractional shortening were 35.3 f 6.4, 34.0 k 7.3, 
Data Sets 2 and 3 
Due to the large degree of interobserver  
m.riability, the echocardingraphic irideotapes were 
reevaluated both at our institution (data set 2) and 
by an  independen t  labora tory  (da ta  set  3 ) .  
Analyses of the EFs derived from the two data sels 
revealed no  significant differences among the 
treatment regimens (p>O.O5) (Table 1). Using data 
set 2 ,  decreases in EF compared with placebo were 
observed in eight, eight, and nine subjects after 
cimetidine, ranitidine, and famotidine, respectively. 
In contrast, with data set 3, decreases occurred in 
only five, three, and two subjects after cimetidine, 
ranitidine, and famotidine, respectively. Although, 
the EFs reported by the independent laboratory 
tended to be higher than those reported by our 
laboratory, the difference between them was not 
significant. 
Independent  of the  da ta  set examined ,  no  
significant differences were detected between the 
overall effect of Hz-receptor antagonists (e.g., mean 
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Figure 1. Ejection fraction (EF%) for each subject during each treatment phase compared wlth placebo 
individual patients, 0 = mean 
The symbols refer to 
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Discussion 
The H2-receptor  antagonis ts  are generally 
regarded as  safe ,  as eiridenced by the i r  low 
frequency of se r ious  adverse react ions.  '' 
Nevertheless, concern exists regarding the potential 
for these agents to cause undesirable cardiovascular 
side effects. In vitro and animal studies suggest 
that they may oppose the action of histamine on 
the myocardium, resulting in negative inotropic 
action.'-' In 1989, oral famotidine,  bu t  not  
cimetidine or  ranitidine, was reported to have 
negative inotropic effects in healthy volunteers.' 
Although these investigators confirmed their 
findings in two subsequent studies,' ' independent 
laboratories failed to suppor t  the results.'-I2 
Potential reasons for the conflicting data include 
differences in the methods of assessing cardiac 
performance, agents studied, dosage regimens, 
du ra t ion  of d r u g  therapy,  t ime of cardiac 
assessment in relationship to drug administration, 
and/or populations studied. Our study intentionally 
employed a design similar to that used by Kirch et 
al,5-7 except that cardiac performance was assessed 
by echocardiography rather  t han  impedance  
cardiography 
Our results indicate that 7 days of therapy with 
cimetidine 800 m g ,  ran i t id ine  300 m g ,  o r  
famotidine 40 m g  is no t  associated wi th  any 
significant alteration in cardiac performance in 
hea l thy  ind iv idua ls  as  de t e rmined  by two-  
dimensional echocardiography and Doppler flow 
studies .  Using duplex  ultrasonography'? and  
exercise echocardiography,' other investigators 
similarly demonstrated that famotidine 40 mg/day 
had no deleterious effect on cardiac function. 
The apparent most likely explanation for the 
disparate results between these investigations', ' 
and the others5-' appears to be the methods by 
which cardiac function was assessed. Kirch et ali-' 
used impedance cardiography, which is based on 
impedance changes in the thorax that result from 
pulsatile flow in the thoracic aorta.16 Although 
impedance cardiography correlates with invasive 
measurements of cardiac output ,  i t  correlates 
poorly with radionuclide ventriculography. 17. l 8  
Echocardiography is commonly performed to 
evaluate myocardial function in the United States. 
The ability to identify changes in  myocardial 
function secondary to drug effects with both two- 
dimensional  echocardiography and  Doppler  
echocardiography is well established.". l9 
It is important to point out that we observed a 
large degree of variability in cardiac response to the 
three agents. This may be explained in part by the 
h i g he r than ex pe c I e d in t e ro b se r\re r va rial] i li t y in 
the assessment of EF. The mean interobserver 
coefficient of variation in ejection fraction was 
11.16% and is higher than that normally reported 
for our laboratory or for other laboratories." It is 
probably due to the range restriction in our EFs. 
In contrast to the wide range normally seen by an 
echocardiography laboratory, all of our EFs were 
essentially within normal limits. 
In addition to interobserver variability, one may 
question whether certain individuals may be more 
sensitive than others to the cardiac effects of these 
agents. Decreases in EF occurred during each of 
the treatment phases. The maximum decreases 
were -12%, -12.5%, and -14.5% for cimetidine, 
ranitidine, and famotidine, respectively. Since our 
study was conducted in healthy volunteers, i t  is 
difficult to ascertain whether these changes would 
represent clinically significant alterations in cardiac 
function in patients with heart failure. 
Alternatively, the variability may be related in 
par t  to the  range of doses  (mg/kg)  o f  H L  
antagonists. Although they were therapeutic doses, 
based o n  subjects '  weight ,  there  is a 2-fold 
variation in them when normalized to milligrams/ 
kilogram. However, similar doses of famotidine 
exerted a negative inotropic effect on  cardiac 
performance in healthy volunteers.', ' 
Another explanation for the changes may relate 
to  the variability in the interpretation of  the 
echocardiograms rather than changes related to a 
specific H2 antagonist. This can be indirectly 
inferred by comparing the echocardiography 
results from data sets 1 and 3. The EFs measured 
by the independent laboratory tended to be higher 
t han  those i n  o u r  laboratory,  which  can  be 
explained by differences in how the EFs were 
calculated. Those calculated by the bullet method 
tend to be higher than those determined using 
Simpson's rule.13 Basing assessment strictly on the 
results from data set 1, one might conclude that a 
slight decrease in EF during therapy might occur 
with these three drugs (p>0.05) .  Conversely, 
basing conclusions strictly on the results from data 
set 3, one might conclude a slight increase in EF is 
associated with the agents (p>0.05). Clearly, the 
magnitude of change in each case is extremely 
small, is highly dependent on the method used to 
calculate the EF, and was not statistically significant 
regardless of data set employed. This may suggest 
that such changes are the result of the variability in 
the methodology and not the result of a specific 
drug. 
With the variance observed, this study had a 
power of 80% to detect a 10% difference in EF 
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means  among  the t rea tments .  The  mean 
differences actually seen during the three treatment 
phases were less than 496, and thus a type I1 error 
may have occurred. However, i t  is important to 
recognize that such small changes in EF (< 4%) are 
probably of little or no clinical significance. 
Based on previous conflicting results regarding 
the  impact  of H2 an tagonis t s  o n  cardiac 
performance in healthy volunteers, we believed 
that it was important to rectify the discrepancy and 
evaluate this population. However, given the 
results of our study in conjunction with others,'-" 
we now firmly believe tha't cimetidine, ranitidine, 
and famotidine do not significantly impair cardiac 
performance in healthy volunteers as determined 
by echocardiography. Our  results cannot  be 
directly extrapolated to critically ill patients or 
those wi th  a h i s tory  of hear t  disease,  o r  to  
intravenous H2 antagonists. Although, we believe 
that our variability in response is secondary to 
inherent variability in methodology, we cannot rule 
out the possibility that certain subjects may be at 
greater risk for cardiovascular adverse effects with 
these drugs. Therefore, it may be prudent to assess 
the  poten t ia l  impact  of these H2-receptor 
antagonists on cardiac performance in patients who 
are at risk for suffering deleterious consequences 
from small changes in EE Specifically, those with 
heart failure may theoretically be more sensitive to 
drug-induced changes in cardiac function and may 
also not be able to compensate for such changes. 
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